Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent

---
Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent
Vote:
0 0
Previous Three in four organizations experienced Microsoft 365 governance incidents in the past year, as AI adoption outpaces the skills to govern it
Next Fashion Trust U.S. Appoints Dr. Omar Mir to Board of Directors; Names Him Lead for 2027 Sustainability Award

Related News

Seegene Obtains IVDR Certification for 30 Diagnostic Assays

DNV SUPPORTS NOUL IN IVDR CERTIFICATION FOR AI-BASED MEDICAL DIAGNOSTIC PRODUCTS

Seegene and Werfen Partner to Collaborate on OneSystem™ Business to Develop Syndromic qPCR Assays

DNV recognized as a Notified Body for Certification under In Vitro Diagnostic Regulation (IVDR)

Anbio Biotechnology Unveils Dry Chemiluminescence Immunoassay (CLIA) Solution: Redefining Diagnostic Precision and Efficiency

DNV SELECTED TO CERTIFY CLASS D DEVICES FOR LEADING U.S. MANUFACTURER UNDER EU IVDR

menu
menu